China Life Private Equity Investment
Shanghaiclpe.com.cn
Overview
China Life Private Equity Investment is a professional private equity investment firm and a subsidiary of China Life Group, established in 2016. The firm focuses on long-term value investing, particularly in the healthcare and technology sectors, and manages the flagship China Life Healthcare Fund.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Cascade Pharmaceuticals, Inc. | Feb 2026 | Series C | Co-investor |
| Jiangsu Vcare Pharmatech Co., Ltd. | Jan 2024 | Series C | Lead |
| Hithium | Jun 2023 | Series C | Lead |
| Xi'an Eswin Material Technology Co., Ltd. | Dec 2022 | Series C | Co-investor |
| Xi'an Eswin Material Technology Co., Ltd. | Jul 2021 | Series B | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
